<DOC>
	<DOCNO>NCT00819325</DOCNO>
	<brief_summary>Patients diabetes bad outcomes percutaneous coronary intervention ( PCI ) procedure , compare patient without diabetes . They increase risk death , heart attack , need procedure due renarrowing coronary narrowing implantation coronary stent . Studies suggest poor control diabetes may partly responsible poor outcome . Thiazolidinedione drug , pioglitazone , improve diabetes control make patient sensitive effect insulin . Preliminary study suggest pioglitazone may also help prevent renarrowing PCI . This study pilot study design determine whether aggressive treatment diabetes routine use drug pioglitazone ( 30mg/day 6 month ) , addition patient 's usual diabetic medication adjust optimize diabetic control ( get glycated hemoglobin &lt; 7 % ) , could reduce amount tissue buildup within stent 6 month , compare group less aggressively treat without pioglitazone usual medication diabetes . An intravascular ultrasound probe use assess extent tissue buildup within stent perform immediately PCI baseline repeat 6 month therapy . The investigator hypothesize aggressive diabetic treatment pioglitazone would reduce extent tissue growth within stent 6 month therapy .</brief_summary>
	<brief_title>Prevention Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone Diabetic Patients</brief_title>
	<detailed_description>Background : Despite drug-eluting stent ( DES ) , diabetic patient remain high risk restenosis poor clinical outcome percutaneous coronary intervention ( PCI ) . Studies suggest poor glycemic control insulin resistance may predictors poor outcome PCI . There conflict study whether strategy improve glycemic control improve outcome PCI . Thiazolidinediones , pioglitazone ( PIO ) , may anti-restenotic benefit , independent glycemic control . Study design : This study single centre prospective , randomize , open-label , blinded-endpoint ( PROBE ) parallel design trial . Type 2 diabetic patient , treat diet oral antidiabetic medication ( sulfonylurea vs. metformin combination ; thiazolidinedione insulin ) , undergo elective urgent PCI stenting eligible . Fifty type 2 diabetic patient randomly assign either : intensive glycemic control : pioglitazone ( PIO ; 30 mg/d x 6 month ) addition titration oral hypoglycemic agent ( OHA ) get HbA1c &lt; 6 % ( PIO : n=25 ) vs. conservative glycemic control : titration OHA get HbA1c &lt; 7 % ( CONTROL : n=25 ) . Intravascular ultrasound ( IVUS ) perform immediately PCI repeat 6 month determine effect instent neointimal plaque volume area . Coronary stenting carried standard fashion , routine use glycoprotein 2b/3a inhibitor procedure . From August 2002 June 2005 , DES permit protocol . After June 2005 , amend protocol allow DES , become routinely used diabetic patient institution , especially vessel size &lt; 3mm and/or lesion length &gt; 15mm . DES use 7 PIO 11 CONTROL subject , bare metal stent ( BMS ) rest . Patients follow clinic visit 1 , 3 6 month . OHA , pioglitazone , adjust stepwise manner order attain HbA1c target . Other concomitant medication , include anti-anginals , lipid-lowering therapy , antihypertensive medication adjust accord clinical need current Canadian guideline . After 6 month treatment , clinically indicate , subject return repeat cardiac catheterization , include repeat coronary angiography IVUS intervene vessel assess serial change luminal dimension . Fasting blood collect plasma glucose , HbA1c , insulin , lipid profile , hs-CRP , adiponectin , leptin , matrix metalloproteinase-9 , interleukin-6 time PCI follow-up IVUS . If patient develop recurrent ischemic symptom 6 month , final IVUS could perform early , find clinically-significant restenosis ( diameter stenosis &gt; 50 % ) . Otherwise , patient still encourage protocol 6 month IVUS follow-up . 41 patient ( n=20 PIO , n=21 CONTROL ) analyzable pair IVUS . Study hypothesis : We hypothesize would significantly less instent neointimal proliferation IVUS 6 month group receive aggressive glycemic control plus thiazolidinedione pioglitazone . We also hypothesize reduction neointimal hyperplasia likely relate improvement glycemic control ( HbA1c ) insulin resistance . Additionally , want explore biochemical predictor ( glucose parameter , lipid , inflammatory marker , adipokines ) neointimal proliferation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>age 30 80 year type 2 diabetes mellitus treat diet oral hypoglycemic agent ( OHA : sulfonylurea metformin alone combination sulfonylurea metformin long metformin dose &lt; 2000 mg/d ) All patient undergo either elective urgent PCI de novo native coronary lesion ( &gt; 70 % diameter stenosis ) vessel ≥ 2.5 mm diameter felt suitable stenting IVUS examination . leave main &gt; 50 % stenosis ongoing congestive heart failure leave ventricular ejection fraction &lt; 30 % primary PCI ST elevation MI use insulin thiazolidinedione therapy ( rosiglitazone pioglitazone ) immediately PCI know intolerance thiazolidinediones creatinine &gt; 130 µmol/L significant liver disease : ALT AST &gt; 3 time upper limit normal , history cirrhosis , hepatitis woman pregnant , breastfeeding , childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>diabetes</keyword>
	<keyword>stent</keyword>
	<keyword>restenosis</keyword>
	<keyword>thiazolidinediones</keyword>
	<keyword>coronary atherosclerosis</keyword>
</DOC>